(VIANEWS) – NVIDIA (NVDA), Xylem (XYL), Exelixis (EXEL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. NVIDIA (NVDA)
223.7% sales growth and 69.17% return on equity
NVIDIA Corporation provides graphics, and compute and networking solutions in the United States, Taiwan, China, and internationally. The company's Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building 3D designs and virtual worlds. Its Compute & Networking segment provides Data Center platforms and systems for AI, HPC, and accelerated computing; Mellanox networking and interconnect solutions; automotive AI Cockpit, autonomous driving development agreements, and autonomous vehicle solutions; cryptocurrency mining processors; Jetson for robotics and other embedded platforms; and NVIDIA AI Enterprise and other software. The company's products are used in gaming, professional visualization, datacenter, and automotive markets. NVIDIA Corporation sells its products to original equipment manufacturers, original device manufacturers, system builders, add-in board manufacturers, retailers/distributors, independent software vendors, Internet and cloud service providers, automotive manufacturers and tier-1 automotive suppliers, mapping companies, start-ups, and other ecosystem participants. It has a strategic collaboration with Kroger Co. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.
Earnings Per Share
As for profitability, NVIDIA has a trailing twelve months EPS of $7.6.
PE Ratio
NVIDIA has a trailing twelve months price to earnings ratio of 71.34. Meaning, the purchaser of the share is investing $71.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 69.17%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 205.5%, now sitting on 44.87B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 410.2% and 380.6%, respectively.
Previous days news about NVIDIA(NVDA)
- According to VentureBeat on Monday, 8 January, "In addition, Nvidia announced that biotech leader Amgen will build AI models trained to analyze one of the world’s largest human datasets on an NVIDIA DGX SuperPOD, a full-stack data center platform, that will be installed at the Amgen’s deCODE genetics’ headquarters in Reykjavik, Iceland.", "We are proud to team with NVIDIA to drive drug discovery innovation and deliver faster, easier and more accurate insights that can accelerate the time it takes to bring new drugs to market."
- According to Zacks on Monday, 8 January, "Here are the three stocks- Medtronic Plc, Stryker Corp. and NVIDIA Corp. which we expect to show solid returns in the coming period, banking on their solid AI-induced growth process.", "The data center end-market business is likely to benefit from the growing demand for generative AI and large language models using graphic processing units (GPUs) based on NVIDIA Hopper and Ampere architectures. "
2. Xylem (XYL)
37.9% sales growth and 7.47% return on equity
Xylem Inc., together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions for the water and wastewater applications in the United States, Europe, the Asia Pacific, and internationally. It operates through three segments: Water Infrastructure, Applied Water, and Measurement & Control Solutions. The Water Infrastructure segment offers various products, including water, storm water, and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment and rental services under the Flygt, Godwin, Sanitaire, Leopold, Wedeco, and Xylem Vue brand names for the transportation and treatment of water. The Applied Water segment provides pumps, valves, heat exchangers, controls, and dispensing equipment systems under the Goulds Water Technology, Bell & Gossett, A-C Fire Pump, Standard Xchange, Lowara, Jabsco, Xylem Vue, and Flojet brand names for residential and commercial building services, and industrial water applications. The Measurement & Control Solutions segment offers smart meters, networked communication devices, data analytics, test equipment, controls, sensor devices, software and managed services, and critical infrastructure services; and software and services, including cloud-based analytics, remote monitoring and data management, leak detection, condition assessment, asset management, and pressure monitoring solutions, as well as testing equipment. This segment sells its products under the Pure Technologies, Sensus, Smith Blair, WTW, Xylem Vue, and YSI brand names. The company markets and sells its products through a network of direct sales force, resellers, distributors, and value-added solution providers. Xylem Inc. was formerly known as ITT WCO, Inc. and changed its name to Xylem Inc. in May 2011. Xylem Inc. was incorporated in 2011 and is headquartered in Washington, District of Columbia.
Earnings Per Share
As for profitability, Xylem has a trailing twelve months EPS of $2.46.
PE Ratio
Xylem has a trailing twelve months price to earnings ratio of 45.54. Meaning, the purchaser of the share is investing $45.54 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.47%.
Moving Average
Xylem’s value is above its 50-day moving average of $103.76 and above its 200-day moving average of $102.97.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 3.3% and 6.3%, respectively.
3. Exelixis (EXEL)
18.4% sales growth and 3.8% return on equity
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Earnings Per Share
As for profitability, Exelixis has a trailing twelve months EPS of $0.29.
PE Ratio
Exelixis has a trailing twelve months price to earnings ratio of 82.55. Meaning, the purchaser of the share is investing $82.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.8%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Exelixis’s EBITDA is 3.68.
Previous days news about Exelixis(EXEL)
- Exelixis (exel) posts preliminary 2023 results, to cut 13% jobs. According to Zacks on Monday, 8 January, "For 2024, Exelixis expects revenues to be between $1.825 billion and $1.925 billion, while product revenues are projected to be in the $1.65-$1.75 billion range. ", "This year, Exelixis is focused on advancing JEWEL-101, the phase I study of XB002 alone and in combination with immunotherapy in a variety of solid tumor settings, with the goal of prioritizing sensitive tumor types for full development."
4. Omega Healthcare Investors (OHI)
12.5% sales growth and 6.17% return on equity
Omega is a REIT that invests in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities. Its portfolio of assets is operated by a diverse group of healthcare companies, predominantly in a triple-net lease structure. The assets span all regions within the U.S., as well as in the U.K.
Earnings Per Share
As for profitability, Omega Healthcare Investors has a trailing twelve months EPS of $0.98.
PE Ratio
Omega Healthcare Investors has a trailing twelve months price to earnings ratio of 31.34. Meaning, the purchaser of the share is investing $31.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.17%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.1%, now sitting on 855.27M for the twelve trailing months.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Oct 29, 2023, the estimated forward annual dividend rate is 2.68 and the estimated forward annual dividend yield is 8.82%.
Sales Growth
Omega Healthcare Investors’s sales growth is 66.6% for the present quarter and 12.5% for the next.
Moving Average
Omega Healthcare Investors’s worth is under its 50-day moving average of $31.48 and below its 200-day moving average of $30.80.
5. Insperity (NSP)
5.6% sales growth and 264.61% return on equity
Insperity, Inc. engages in the provision of human resources (HR) and business solutions to improve business performance for small and medium-sized businesses. It offers its HR services through its Workforce Optimization and Workforce Synchronization solutions that include a range of human resources functions, such as payroll and employment administration, employee benefits, workers' compensation, government compliance, performance management, and training and development services. The company also provides Insperity Premier, a cloud-based human capital management platform that offers professional employer organization HR outsourcing solutions to its clients; people management services; and employer liability management services, as well as solutions for middle market. In addition, it offers MarketPlace, an e-commerce portal that offers a range of products and services; and Workforce Acceleration, a human capital management and payroll services solution; time and attendance; performance management; recruiting; employment screening; retirement; and insurance services. The company was formerly known as Administaff, Inc. and changed its name to Insperity, Inc. in March 2011. Insperity, Inc. was founded in 1986 and is headquartered in Kingwood, Texas.
Earnings Per Share
As for profitability, Insperity has a trailing twelve months EPS of $4.92.
PE Ratio
Insperity has a trailing twelve months price to earnings ratio of 23.9. Meaning, the purchaser of the share is investing $23.9 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 264.61%.
Sales Growth
Insperity’s sales growth is 6.3% for the present quarter and 5.6% for the next.
